Assessment of α1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory

British Journal of Clinical Pharmacology

Volumn 63, Issue 4, 2007, Pages 394-403

  Ito, Kaori ^a,b   Ohtani, Hisakazu ^a,c   Sawada, Yasufumi ^a,c  

^a KYUSHU UNIVERSITY   (Japan)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Doxazosin; Pharmacodynamics; Pharmacokinetics; Receptor binding

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; PLACEBO; TAMSULOSIN; TERAZOSIN; ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL TRACT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; STANDARD; TABLET FORMULATION; THEORY; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE; MALE; METABOLISM; MICTURITION; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; DOXAZOSIN; HUMANS; MALE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC; URINATION;

EID: 33947263718     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02783.x     Document Type: Article

References (32)

1. Walsh PC. Benign prostatic hyperplasia. In: Campbell's Urology, 6th edn, ed. Walsh PC, Chapter 25. 1992; 1: 1009-28.
2. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol 1982; 128: 836-9.
3. Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indication for therapeutic intervention. Urol Clin North Am 1990; 17: 509-16.
4. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, for the finasteride study group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185-91.
5. Yamada Y, Takayanagi R, Tsuchiya K, Ito K, Ohtani H, Sawada Y, Iga T. Assessment of systemic adverse reactions induced by ophthalmic beta-adrenergic receptor antagonists. J Ocul Pharmacol Ther 2001; 17: 235-48.
6. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 1980; 225: 7108-17.
7. Sawada Y, Yamada Y, Iga T. Quantitative evaluation of pharmacological effects and adverse effects based on receptor occupancy theory. Yakugaku Zasshi - J Pharmaceut Soc Japan 1997; 117: 65-90.
8. Yamada Y, Shibuya F, Hamada J, Sawada Y, Iga T. Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. J Pharmacokinet Biopharm 1995; 23: 131-45.
9. Fawzy A, Vashi V, Chung M, Dias N, Gaffney M. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment if benign prostatic hyperplasia. Urology 1999; 53: 329-35.
10. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-5.
11. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol 1986; 21 (Suppl. 1): 19S-35S.
12. Pfizer Pharmaceutical Inc. Doxazosin Investigator Brochure 2001.
13. Weiss R, Knight BP, Bahu M, Zivin A, Souza J, Goyal R, Daoud E, Man KC, Strickberger SA, Halter JB, Morady F. Cardiac electrophysiologic effects of norepinephrine in human being. Am Heart J 1998; 135: 945-51.
14. Buxton IL, Bruntoon LL. Alpha-adrenergic receptors on rat ventricular myocytes: characteristics and linkage to cAMP metabolism. Am J Physiol Heart Circ Physiol 1986; 251: H307-H313.
15. Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutics system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87.
16. Beal SL, Sheiner LB. NONMEM Users Guide, Part I-VIII. San Francisco: NONMEM Project Group C255, University of California at San Francisco 1988.
17. 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 587-96.
18. Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJJ, Eichler HG. Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol 1998; 54: 367-73.
19. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
20. Sonders RC. Pharmacokinetics of terazosin. Am J Med 1986; 80 (Suppl. 5B): 20-4.
21. Patterson SE. Terazosin kinetics after oral and intravenous doses. Clin Pharmacol Ther 1985; 38: 423-7.
22. 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129-44.
23. Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 1980; 5: 365-76.
24. Hayashi M, Hanano M, Shintani H. Relative bioavailability of prazosin hydrochloride tablet in man. Jpn J Clin Pharmacol Ther 1978; 9: 385-94.
25. Elliott HL, Meredith PA, Reid JL. Pharmacokinetic overview of doxazosin. Am J Cardiol 1987; 59: 78G-81G.
26. Yamada S, Tanaka C, Kimura R, Kawabe K. Alpha1-adrenoceptors in human prostate. Characterization and binding characteristics of alpha1-antagonists. Life Sci 1994; 54: 1845-54.
27. Drach GW, Layton TN, Binard WJ. Male peak urinary flow rate: relationships to volume voided and age. J Urol 1979; 122: 210-4.
28. MacDiarmid SA, Emery RT, Ferguson SF, McGuirt-Franklin R, McIntyre WJ, Johnson DE. A randomized double-blind study assessing 4 versus 8 mg doxazosin for benign prostatic hyperplasia. J Urol 1999; 162: 1629-32.
29. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200.
30. 1-acid glycoprotein. J Clin Pharmacol 1996; 36: 1029-38.
31. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
32. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000; 20: 423-51.